Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

First selective ganglioside biosynthesis inhibitors identified at Zacharon Pharma

May 2, 2011

R-507 and R-545 reduce acute cellular rejection in vivo

May 2, 2011

New bivalent immunotoxin shows promise to treat solid tumors

May 2, 2011

CH-4938056 targets microtubule-associated protein 4 to confer antitumor activity

May 2, 2011

AY-4 inhibits tumor growth in model of head and neck cancer

April 29, 2011

Genetic markers of prostate cancer mortality identified in castration-resistant disease

April 29, 2011

Antibody-drug conjugate BAY-94-9343 is active against mesothelin-expressing tumors

April 29, 2011

Second-generation tumor metabolism inhibitor PENAO shows promise in vitro and in vivo

April 29, 2011

TTAC-0001 displays antitumor efficacy in various models

April 29, 2011

AZD-4547 shows preclinical potential to treat solid tumors

April 29, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...